Madrigal Pharmaceuticals, Inc.
MDGL
주식 순위
#1971
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical... Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
주가
$458.30
시가총액
$10.59B
변동 (1일)
-1.98%
변동 (1년)
6.58%
국가
US
거래 Madrigal Pharmaceuticals, Inc. (MDGL)
카테고리
Healthcare
Madrigal Pharmaceuticals, Inc. (MDGL)의 주가 이력
최고 종가: $472.49 (2026-10-01 기준)
최저 종가: $322.31 (2007-02-01 기준)
최저 종가: $322.31 (2007-02-01 기준)
Madrigal Pharmaceuticals, Inc.의 주가 이력 (2007 ~ 2026)
연간 주가 성과
| 연도 | 성과 |
|---|---|
| 2026 (TTM) | -11.55% |
| 2025 | 85.56% |
| 2024 | 36.19% |
| 2023 | 46.99% |
| 2022 | 95.20% |
| 2021 | -32.68% |
| 2020 | 16.63% |
| 2019 | -6.63% |
| 2018 | 32.71% |
| 2017 | 414.16% |
| 2016 | 26.67% |
| 2015 | -87.18% |
| 2014 | -42.14% |
| 2013 | -44.12% |
| 2012 | 87.26% |
| 2011 | -19.61% |
| 2010 | 10.34% |
| 2009 | 1.71% |
| 2008 | -25.83% |
| 2007 | 0.00% |
유사 기업 또는 경쟁사의 주가
| 회사 | 주가 | 변동률 1년% | 국가 |
|---|---|---|---|
| $527.18 | 23.67% |
US
|
|
| $251.29 | 814.11% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $890.85 | 6.72% |
NL
|
|
| $752.87 | 7.40% |
CH
|
